Close this search box.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation® Canada

Precision Medicine
for Myalgic Encephalomyelitis
Drug Discovery and ClinicaI Trials (REMEDIAL)

  • From our MAESTRO project, we have seen that the profile of circulating microRNA can distinguish between ME/CFS and Fibromyalgia (FM) patients.
  • Our diagnostic panel of 11 circulating microRNA can be used (without induction of PEM) to identify individuals suffering of ME/CFS, FM or having both conditions.
  • We have also shown that miR-150-5p is associated with POTS/OI in ME/CFS patients. We proposed that miR-150- 5p triggers POTS/OI through two distinct mechanisms:
    • Mechanism 1: Elevation of miR-150-5p expression occurs in ME/CFS patients with POTS/OI and block the translation of SLC6A2 mRNA resulting in a norepinephrine transporter (NET) deficiency.
    • Mechanism 2: Conversely, a severe reduction of miR-150- 5p expression induces a similar effect by increasing the EZH2 expression, which leads to a transcriptional repression of SLC6A2 gene, lowering NET levels. We are also exploring the role of circulating thrombospondin-1 (TSP-1) in the regulation of soluble SMPDL3B production.
    • Lastly, we have identified 8 targets as potential therapeutic options and will be exploring these further–specifically how to increase, reduce, or block these potential biomarkers of ME/CFS.


Our study will couple a deep phenotyping
characterization of ME/CFS patients to the
development of cellular and animal models
for repurposing current drugs to accelerate
the proof-of-concept of different therapeutic
interventions for ME/CFS. Indeed, precision
medicine is essential to address the clinical
complexity of ME/CFS and to identify the
best therapeutic options to cure ME/CFS.

Three researchers, two men and a woman in a lab. The man in the foreground is recording findings.


  • Deep phenotyping of ME patients through precision medicine.
  • Development of cellular and mouse models for the validation of targets.
  • Preparation and launch of pilot phase 2b clinical trials..